Search | Clinical Trials Finder

Conditions: Pancreatic Trauma, Pancreatic Duct Injury, Pancreas Necrosis, Pancreas Cyst, Pancreas; Fistula, Pancreas Abscess, Intra-Abdominal Abscess, Anastomotic Leak, Pancreas Injury
Interventions: Exploratory laparotomy; Procedure
Lead sponsor: Kern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Bakersfield, California

Conditions: Premature, Premature Lungs, Ventilator Lung; Newborn, Rectus Abdominis
Interventions: NeoBelly Band; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 26 Weeks to 31 Weeks
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Dehydration in Children, Dehydration
Interventions: LifeFlow; Device
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 1 Month to 18 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Obesity, Abdominal
Interventions: Supine spirometry, MIPs and MEPs; Diagnostic Test
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Abdominal Aortic Aneurysm
Interventions: Endovascular AAA repair with InCraft®; Device
Lead sponsor: Cordis US Corp.; Industry
Eligibility: 20 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Abdominal Pain, Gastritis, Gastric Ulcer, Gastric Cancer
Interventions: MAGNET; Device
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Gastroschisis
Interventions: Glycerin Suppository; Drug
Lead sponsor: Indiana University; Other
Eligibility: 1 Day to 1 Year
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Cancer of the Lung, Abdominal Cancer
Interventions: Not listed
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 86 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Abdominal Obesity, Growth Hormone Deficiency
Interventions: Growth hormone releasing hormone (GHRH) 1-44, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Migraine, Abdominal Pain
Interventions: thermal biofeedback, relaxation training, cognitive coping skills, parent education; Behavioral
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 7 Years to 17 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Patient Compliance, Medication Adherence, Medication Non-Adherence
Interventions: Information prescriptions; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 3,940 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Baltimore, Maryland • Columbia, Maryland

Conditions: Abdominal Aortic Aneurysm (AAA)
Interventions: Endovascular Aneurysm Repair; Procedure
Lead sponsor: Minneapolis Heart Institute Foundation; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Colorectal Carcinoma, Peritoneal Carcinomatosis
Interventions: Laparotomy+ HIPEC +/- CRS; Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Irritable Bowel Syndrome With Diarrhea
Interventions: CIN-103, Placebo; Drug
Lead sponsor: CinPhloro Pharma, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 53
States / cities: Dothan, Alabama • Huntsville, Alabama • Phoenix, Arizona + 45 more

Conditions: Abnormal Uterine Bleeding, Uterine Bleeding, Fibroid Uterus, Surgery
Interventions: Total Laparoscopic Hysterectomy; Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Extrahepatic Bile Duct Cancer, Nausea, Vomiting, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions: aprepitant, gemcitabine hydrochloride, capecitabine, fluorouracil, radiation therapy, questionnaire administration, quality-of-life assessment, nausea and vomiting therapy, management of therapy complications; Drug · Procedure · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Diabetes Mellitus, Type 2, Insulin Resistance
Interventions: HydraSolve T2D™; Device
Lead sponsor: Medality Medical; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Abdominal Pain, Deglutition Disorders, Fecal Incontinence, Nausea, Diarrhea, Constipation, Gastroesophageal Reflux
Interventions: AEGIS (Automated Evaluation of Gastrointestinal Symptoms); Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hernia, Ventral, Ileus
Interventions: Neostigmine / Glycopyrrolate, Sugammadex; Drug
Lead sponsor: Clayton Petro; Other
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Abdominal Aortic Aneurysm (AAA), Aorto-iliac Aneurysm, Juxtarenal Aneurysm
Interventions: Zenith® Fenestrated AAA Endovascular Graft; Device
Lead sponsor: Cook Research Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 6
States / cities: Sacramento, California • Aurora, Colorado • Kalamazoo, Michigan + 3 more

Conditions: Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor, Localized Extrahepatic Bile Duct Cancer, Localized Gallbladder Cancer, Localized Gastrointestinal Carcinoid Tumor, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Primary Peritoneal Cavity Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Adult Soft Tissue Sarcoma, Recurrent Colon Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Small Intestine Cancer, Recurrent Uterine Sarcoma, Regional Gastrointestinal Carcinoid Tumor, Small Intestine Adenocarcinoma, Small Intestine Leiomyosarcoma, Small Intestine Lymphoma, Stage 0 Non-small Cell Lung Cancer, Stage I Adult Soft Tissue Sarcoma, Stage I Colon Cancer, Stage I Gastric Cancer, Stage I Non-small Cell Lung Cancer, Stage I Ovarian Epithelial Cancer, Stage I Ovarian Germ Cell Tumor, Stage I Pancreatic Cancer, Stage I Rectal Cancer, Stage I Uterine Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage II Colon Cancer, Stage II Gastric Cancer, Stage II Non-small Cell Lung Cancer, Stage II Ovarian Epithelial Cancer, Stage II Ovarian Germ Cell Tumor, Stage II Pancreatic Cancer, Stage II Rectal Cancer, Stage II Uterine Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Colon Cancer, Stage III Gastric Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Uterine Sarcoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adult Soft Tissue Sarcoma, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Uterine Sarcoma, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions: EF5, motexafin lutetium, pharmacological study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Abdominal Pain
Interventions: radio-opaque adhesive skin markers; Device
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Abdominal Aortic Aneurysm
Interventions: TREO Abdominal Stent-Graft System; Device
Lead sponsor: Bolton Medical; Industry
Eligibility: 18 Years and older
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 33 more

Conditions: Irritable Bowel Syndrome
Interventions: Placebo, Camlipixant; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 108
States / cities: Anniston, Alabama • Guntersville, Alabama • Mobile, Alabama + 88 more

Search by objective public record fields.

A Retrospective Analysis of Pancreatic Injuries and Treatment Outcomes

Baby ABS (Abdominal Binder Study)

LifeFlow Fluid Study- Non- Critical Pediatric Patients Having a Trans Abdominal Ultrasound

Effect of Body Position on Spirometry in Abdominal Obesity.

A Multicenter, Open Label, Prospective, Non-randomized Study of the InCraft® Stent Graft System in Subjects With Abdominal Aortic Aneurysms (INSPIRATION)

MAGNET (Magnetically Controlled Capsule for Assessment of Gastric Mucosa in Symptomatic Patients)

Evaluation of Glycerin Suppositories to Improve Bowel Function in Gastroschisis

Investigating the Improvement in 4D CT Images Using AV Biofeedback

Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese

Migraine and Recurrent Abdominal Pain in Children

Impact of Information Prescriptions on Medication Adherence in Emergency Department (ED) Patients

Endovascular Aneurysm Repair (EVAR) Gate Study

Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases

Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).

Outcomes on Abdominal Versus Vaginal Morcellation At Time of Hysterectomy

Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer

Evaluation of Intra-Abdominal Fat Extraction Using HydraSolve T2D™ in Obese Subjects With Type 2 Diabetes

Evaluating the Impact of Automated Evaluation of Gastrointestinal Symptoms (AEGIS) on Clinical Outcomes

The Impact of Sugammadex on Ileus After Abdominal Wall Reconstruction

Fenestrated AAA Endovascular Graft Post-Approval Study

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

Correlation of Location of Abdominal Tenderness With Acute CT Abnormalities in Emergency Department Patients

Post-Approval Study of the TREO Abdominal Stent-Graft System

A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)